Breakpoints cover image

#60 – Going MAD for Non-COVID ID Literature: A Year in Review LIVE from MAD-ID

Breakpoints

00:00

Deloro Back-Damned: A Novel Beta Lactamase Inhibitor

The next late breaker that they presented at Ekma 2022 was the attack trial. The attack trial evaluated so back-damned Alora back-dam versus Callistin in patients with Asinita bermani I have that or bloodstream infection. Now our dear friend Jason Pope already gave away the punchline in his fabulous stock yesterday but alas I'm going to go through these data anyway because this is good stuff. Deloro back-dam is a novel beta lactamase inhibitor that inhibits class A, class C and class D beta lactamases.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app